2024-515534-32-00招募中2 期
An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema
Klinikum rechts der Isar der TU Muenchen AöR2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2024年10月24日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
- 试验地点
- 2
- 主要终点
- Percent change in EASI score from baseline to week 16
研究概览
简要总结
To evaluate the efficacy of Dupilumab in patients with nummular eczema.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Clinically confirmed diagnosis of NE
- •Biopsy-proven, meaning histology consistent with eczema (including PAS-staining).
- •EASI score ≥
- •PGA ≥ 3 on a 5 point scale.
- •Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.
- •Female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country at screening. This includes: A woman who is not capable of bearing a child is defined as follows: post-menopausal (12 months natural (spontaneous) amenorrhea or 6 months spontaneous amenorrhea with serum-FSH-values (follicle-stimulating hormone) of >40 mIU/mL); 6 weeks after a bilateral ovariectomy with or without hysterectomy or sterilization by means of tubal ligation A woman capable of bearing child is defined as follows: a woman who is physiologically capable of becoming pregnant, including women whose occupation, lifestyle or sexual orientation exclude sexual intercourse with a male partner and women whose partners have been sterilized by vasectomy or other measures. Medically-approved methods of contraception can include the following: hormonal contraceptives or intrauterine device. Acceptable preventive measures can include total abstinence at the discretion of the investigator, in cases where compliance is ensured because of the study participant’s age, occupation, lifestyle or sexual orientation. Periodical abstinence (e.g. calendar, ovulation, symptothermal methods or abstinence until the 4th day after the ovulation) as well as coitus interruptus are not acceptable methods of contraception. Effective contraception (CTFG guideline) for women of childbearing potential should be used throughout the study, including during the follow-up period or at least 120 days after last dose, whichever is longer (elapse of 4-5 half-lives). The event of pregnancy, Dupilumab should be immediately discontinued.
- •History of continuous use of at least mid-potency topical steroids for the last 8 weeks.
- •Age 18-85 years of age, body weight ≥ 40 kg and ≤ 160 kg.
- •Signed informed consent from patient.
排除标准
- •Permanent severe diseases, especially those affecting the immune system.
- •Any other medical or psychological condition including relevant laboratory abnormalities at screening that, in the opinion of the investigator, suggest a new and/or insufficiently understood disease, may present an unreasonable risk to the study patient as a result of his/her participation in this clinical trial, may make patient's participation unreliable, or may interfere with study assessments. The specific justification for patients excluded under this criterion will be noted in study documents (chart notes, CRF, etc).
- •Planned major surgical procedure during the patient's participation in this study.
- •Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor tolerability or lack of access to veins).
- •Active chronic or acute infection requiring systemic treatment within 2 weeks before the baseline visit, independent from of the cuntaneous dysbiosis found in NE.
- •Treatment with an investigational drug within 8 weeks before the baseline visit*.
- •Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit
- •Diagnosed active endoparasitic infections or at high risk of these infections.
- •Evidence of severe renal dysfunction defined as: eGFR < 30 ml/min/1,73 m^2 (calculated using the cockroft gault formula f) at screening (Visit 1)
- •Evidence of significant hepatic disease defined as: At screening (Visit 1): - Alkaline phosphatase >3x upper limit of normal (ULN) or alkaline phosphatase >2,5x ULN and total bilirubin > 2xULN or - Aspartate transaminase (AST, SGOT]) and alanine transaminase (ALT, SGPT]) > 2.5x upper limit of normal (ULN).
- •Patients who are considered potentially unreliable or where it is envisaged the patient may not consistently attend scheduled study visits.
- •Known history of human immunodeficiency virus (HIV) infection.
- •Inability or unwillingness to undergo repeated punch biopsies.
- •History of allergy to any component of the study medication.
- •Evidence of acute contact dermatitis at screening.
- •Evidence of Zink deficiency defined as Zink level < 20 µg/dL in serum.
- •History of important side effects of medium potency topical corticosteroids (eg, intolerance to treatment, hypersensitivity reactions*, significant skin atrophy, systemic effects), as assessed by the investigator or patient’s treating physician.
- •≥30% of the total lesional surface located on areas of thin skin that cannot be safely treated with medium potency TCS (eg, face, neck, intertriginous areas, genital areas, areas of skin atrophy) at baseline.
- •Planned or anticipated use of any prohibited medications and procedures during study treatment.
- •Participation in a prior clinical trial is permitted, as long as adequate wash-out periods and exclusion criterion #4 are taken into consideration.
- •Established diagnosis of Hepatitis B viral infection at the time of screening.
- •Pregnancy or breast feeding.
- •Established diagnosis of hepatitis C viral infection at the time of screening.
- •History of past or current tuberculosis or other mycobacterial infection.
- •Presence of skin comorbidities that may interfere with study assessments. This includes, but is not limited to, conditions like scabies, seborrheic dermatitis, Cutaneous T cell Lymphoma, Psoriasis, etc.
- •Malignancy within 5 years of the screening visit excluding local cutaneous squamous cell
- •Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study. Examples include, but are not limited to patients with short life expectancy, patients with major congenital malformations, patients with cardiovascular conditions (eg, major, clinically significant congenital cardiovascular abnormalities), severe renal conditions, hepato-biliary conditions (eg, Child-Pugh class B or C), active major autoimmune diseases (eg, lupus, inflammatory bowel disease etc.), other severe endocrinological, gastrointestinal, metabolic, pulmonary, neurological or lymphatic diseases. The specific justification for patients excluded under this criterion will be noted in study documents (chart notes, case report forms [CRF], etc).
结局指标
主要结局
Percent change in EASI score from baseline to week 16
Percent change in EASI score from baseline to week 16
次要结局
- Number of Patients Achieving an Improvement (Decrease) in Physician Global Assessment (PGA) by two or more points at week 16 as compared to week 0 or achieving an absolute PGA of 0 or 1 at Week 16.
- Eczema Area and Severity Index (EASI) 50 score at week 16 The proportion of subjects who achieve at least a 50% reduction in the EASI score at Week 16 compared to week 0 (Baseline).
- Significant histological improvement at week 16. Assessed by reduction of epidermal thickness > 30% or reduction of inflammatory infiltrate > 50 % compared to histological findings on baseline.
- Change from Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16.
- Change from Baseline in Pruritus Visual Analog Scale (VAS) Score at Week 16.
- Change from Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) Score at Week 16.
- Safety of Dupilumab will be assessed by Evaluating Adverse Events (AEs).
研究者
Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein
Scientific
Klinikum rechts der Isar der TU Muenchen AöR
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)NeurodermatitisNCT04183335Sanofi151
已完成
3 期
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)NeurodermatitisNCT04202679Sanofi160
招募中
3 期
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)2023-503999-24-00AstraZeneca AB437
已完成
3 期
Dupilumab in Japanese Patients With Atopic DermatitisAtopic DermatitisNCT04678882Sanofi62
已完成
3 期
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)AsthmaNCT02414854Sanofi1,902